All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Andrew Brunner, Massachusetts General Hospital, Boston, US. We asked, What new treatments are available for high-risk myelodysplastic syndromes (MDS)? What does this mean for patients?
What new treatments are available for high-risk MDS? What does this mean for patients?
In this video, Brunner discusses novel treatment options available for high-risk MDS and the the implications for patients. He also discusses the findings from an ongoing phase II and III trial (NCT03066648), investigating the efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with high-risk MDS.
Oral formulations of cedazuridine and decitabine for patients with MDS
Hypomethylating agents (HMAs), such as azacitidine and decitabine, are the main treatment options for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
Is there synergy between anti-TIM-3 therapy and HMAs in the treatment of MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uma Borate, OHSU Knight Cancer Institute, Portland, US. We asked: Is there...
Subscribe to get the best content related to MDS delivered to your inbox